PMID- 32375962
OWN - NLM
STAT- MEDLINE
DCOM- 20210628
LR  - 20210628
IS  - 1539-6304 (Electronic)
IS  - 1088-5412 (Linking)
VI  - 41
IP  - 3
DP  - 2020 May 1
TI  - Serum immunoglobulin E reactivity to cross-reacting panallergen components in 
      north-eastern Poland patients pollen sensitized.
PG  - 183-191
LID - 10.2500/aap.2020.41.200002 [doi]
AB  - Background: The presence of immunoglobulin E (IgE), which cross-reacts with 
      allergen components, such as profilins, polcalcins, and cross-reacting 
      carbohydrate determinants (CCD), creates a problem when selecting patients for 
      allergen immunotherapy by using conventional methods. The aim of this study was 
      to evaluate the prevalence of sensitization to profilins, polcalcins, and CCDs in 
      patients with seasonal pollen allergic rhinitis. Methods: The study was performed 
      on a group of 112 patients with seasonal pollen allergic rhinitis, ages 14 to 55 
      years, with sensitization to at least one seasonal allergen (IgE > 0.7 kUA/L). 
      The presence of IgE sensitization to recombinant (r) Bet v 2, rPhl p 12, rBet v 
      4, rPhl p 7, and CCDs, in addition to rBet v 1, rPhl p 1, rPhl p 5, was evaluated 
      by using a multiparameter immunoblot. Results: Among the studied patients, 64.3, 
      80.4, and 41.1% were sensitized to birch, timothy grass, and mugwort pollen, 
      respectively. Sensitization to profilins rBet v 2/Phl p 12 was demonstrated in 
      28.6%, to polcalcins Bet v 4/Phl p 7 in 8.9%, and to CCDs in 25%. In 29.3%, serum 
      IgE reactivity to any of the cross-reactive components could be demonstrated. 
      Serum IgE reactivity to rBet v 2 was always accompanied by IgE reactivity to rPhl 
      p 12, and IgE reactivity to rBet v 4 was always accompanied by IgE reactivity to 
      rPhl p 7. Among the patients with pollinosis co-sensitized to at least two 
      allergen sources according to extract-based diagnosis, possible false-positive 
      results due to sensitization to cross-reactive components were detected in 17.9%. 
      Conclusion: Evaluation of sensitization to cross-reacting components may be 
      useful in evaluation of patients with pollen allergy who are being assessed for 
      allergen immunotherapy to optimize the constitution of their immunotherapy 
      vaccines.
FAU - Kowal, Krzysztof
AU  - Kowal K
AD  - From the Department of Experimental Allergology and Immunology, Medical 
      University of Bialystok, Poland.
FAU - Pampuch, Agnieszka
AU  - Pampuch A
AD  - Department of Allergology and Internal Medicine, Medical University of Bialystok, 
      Poland.
FAU - Sacharzewska, Ewa
AU  - Sacharzewska E
AD  - From the Department of Experimental Allergology and Immunology, Medical 
      University of Bialystok, Poland.
FAU - Swiebocka, Ewa
AU  - Swiebocka E
AD  - Allergy Clinic, Children's Clinical Hospital, Medical University of Bialystok, 
      Bialystok, Poland.
FAU - Siergiejko, Zenon
AU  - Siergiejko Z
AD  - Laboratory of Respiratory Diagnostics and Bronchoscopy, Medical University of 
      Bialystok, Bialystok, Poland.
FAU - Siergiejko, Grzegorz
AU  - Siergiejko G
AD  - Department of Pediatrics, Gastroenterology, Hepatology, Nutrition and 
      Allergology, Medical University of Bialystok, Poland.
FAU - Chruszcz, Maksymilian
AU  - Chruszcz M
AD  - Department of Chemistry and Biochemistry, University of South Carolina, Columbia, 
      South Carolina, and.
FAU - DuBuske, Lawrence
AU  - DuBuske L
AD  - Department of Allergy and Immunology, George Washington University School of 
      Medicine and Health Sciences, Washington, D.C.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Allergy Asthma Proc
JT  - Allergy and asthma proceedings
JID - 9603640
RN  - 0 (Allergens)
RN  - 0 (Antigens, Plant)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (Profilins)
RN  - 37341-29-0 (Immunoglobulin E)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Allergens/*immunology
MH  - Antigens, Plant/*immunology
MH  - Artemisia/immunology
MH  - Betula/immunology
MH  - Calcium-Binding Proteins/*immunology
MH  - Cross Reactions/immunology
MH  - Desensitization, Immunologic
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*immunology
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Phleum/immunology
MH  - Poland
MH  - Pollen/*immunology
MH  - Profilins/*immunology
MH  - Rhinitis, Allergic, Seasonal/*immunology/therapy
MH  - Young Adult
EDAT- 2020/05/08 06:00
MHDA- 2021/06/29 06:00
CRDT- 2020/05/08 06:00
PHST- 2020/05/08 06:00 [entrez]
PHST- 2020/05/08 06:00 [pubmed]
PHST- 2021/06/29 06:00 [medline]
AID - 10.2500/aap.2020.41.200002 [doi]
PST - ppublish
SO  - Allergy Asthma Proc. 2020 May 1;41(3):183-191. doi: 10.2500/aap.2020.41.200002.